Compare · APR vs BSX
APR vs BSX
Side-by-side comparison of Apria Inc. (APR) and Boston Scientific Corporation (BSX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both APR and BSX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $60.90B, about 46.1x APR ($1.32B).
- BSX has hit the wire 2 times in the past 4 weeks while APR has been quiet.
- BSX has more recent analyst coverage (25 ratings vs 6 for APR).
- Company
- Apria Inc.
- Boston Scientific Corporation
- Price
- $37.49-0.01%
- $62.06-5.52%
- Market cap
- $1.32B
- $60.90B
- 1M return
- -
- -11.05%
- 1Y return
- -
- -39.23%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 2
- Recent ratings
- 6
- 25
Apria Inc.
Apria, Inc. provides integrated home healthcare equipment and related services in the United States. The company offers home respiratory therapies, including the supply of stationary and portable home oxygen equipment, and non-invasive ventilators; obstructive sleep apnea therapy devices comprising continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services; and negative pressure wound therapy products. It also provides a range of home medical equipment and other products, and services for patients with home care needs; and clinical and administrative support services, and related products and supplies to patients. The company was incorporated in 2018 and is headquartered in Indianapolis, Indiana.
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Latest APR
- SEC Form SC 13G/A filed by Apria Inc. (Amendment)
- SEC Form 15-12B filed by Apria Inc.
- Executives Sell Over $640M Of 5 Stocks
- SEC Form 4: Walker Robert P. returned $192,450 worth of shares to the company (5,132 units at $37.50), closing all direct ownership in the company (tax liability)
- SEC Form 4: Apria Holdings Llc sold $532,031,812 worth of shares (14,187,515 units at $37.50)
- SEC Form 4 filed by Snyder Lynn Shapiro to satisfy withholding obligation
- SEC Form 4: Scally Celina M. returned $166,425 worth of shares to the company (4,438 units at $37.50), closing all direct ownership in the company (tax withholding)
- SEC Form 4 filed by Lee Christopher G (withholding tax)
- SEC Form 4: Morris Debra L exercised 8,190 shares at a strike of $2.07, covered exercise/tax liability with 4,289 shares and returned $317,288 worth of shares to the company (8,461 units at $37.50), closing all direct ownership in the company to cover taxes
- SEC Form 4: Zafirovski Mike S returned $4,604,062 worth of shares to the company (122,775 units at $37.50), closing all direct ownership in the company (withholding tax)
Latest BSX
- Boston Scientific Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Boston Scientific announces results for first quarter 2026
- SEC Form EFFECT filed by Boston Scientific Corporation
- SEC Form 424B3 filed by Boston Scientific Corporation
- Boston Scientific downgraded by Raymond James with a new price target
- Boston Scientific announces conference call discussing first quarter 2026 results
- Amendment: SEC Form S-4/A filed by Boston Scientific Corporation
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpoints
- HI-PEITHO trial demonstrates Boston Scientific EKOS™ Endovascular System is superior to standard of care for treatment of acute pulmonary embolism